首页 | 本学科首页   官方微博 | 高级检索  
     


Rilotumumab in combination with epirubicin,cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label,dose de-escalation phase 1b study and a double-blind,randomised phase 2 study
Authors:Timothy Iveson  Ross C Donehower  Irina Davidenko  Sergey Tjulandin  Andrzej Deptala  Mark Harrison  Somanath Nirni  Kuntegowdanahalli Lakshmaiah  Anne Thomas  Yizhou Jiang  Min Zhu  Rui Tang  Abraham Anderson  Sarita Dubey  Kelly S Oliner  Elwyn Loh
Affiliation:1. University Hospital Southampton, Southampton, UK;2. Johns Hopkins Cancer Center, Baltimore, MD, USA;3. State Institution of Public Health “Regional Clinical Oncology Dispensary”, Krasnodar, Russia;4. Russian Cancer Research Center, Moscow, Russia;5. Central Clinical Hospital MSW, Warsaw Medical University, Warsaw, Poland;6. Mount Vernon Hospital, Northwood, UK;7. Indo-American Cancer Institute and Research Centre, Hyderabad, India;8. Kidwai Memorial Institute of Oncology, Bangalore, India;9. University of Leicester, Leicester, UK;10. Amgen Inc, Thousand Oaks, CA, USA;11. Amgen Inc, South San Francisco, CA, USA
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号